I-Mab (NASDAQ:IMAB) said on Thursday that it has signed an agreement to acquire Bridge Health Biotech. As part of the deal, I-Mab will provide an initial payment of $1.8M to Bridge Health ...

China-based biotech company I-Mab said on Friday that AbbVie has terminated a 2020 deal to co-develop and market I-Mab's lead cancer drug candidate lemzoparlimab.

Now, the biotech has shared details of the human cost of its rethink. Seeking to right-size the company to reflect its focus, I-Mab completed a 27% reduction in its workforce Tuesday. I-Mab ended ...

I-MAB Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024 ...

Chinese biotechnology firm I-Mab is exploring options including a sale of the business amid takeover interest from other global drugmakers, according to people familiar with the matter.

Terms of both deals were kept under wraps, but I-Mab is known for making a splash with deals. The company secured $180 million upfront and up to $1.74 billion in biobucks from AbbVie last ...